[Successful topical treatment of chronic cutaneous leishmaniasis with paromomycin sulfate (15%) and methylbenzethonium chloride (12%)].
A 19-year-old male patient with chronic cutaneous leishmania is was treated topically with paromomycin sulphate (15%) and methylbenzethonium chloride (12%) in petrolatum album. After application twice daily for two periods of 32 and 44 days the lesions were completely healed. Previous treatment for 9 months with ketoconazole (400 mg/day) together with the topical application of thiabendazole (2.5%) in base had been unsuccessful. No major side effects were observed after paromomycin sulphate application.
Schallreuter
K U
KU
Hautklinik, Universitätskrankenhauses Eppendorf, Hamburg.
Lemke
K R
KR
D000287:Administration, Topical; D000328:Adult; D000981:Antiprotozoal Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001558:Benzethonium / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005148:Facial Dermatoses / Q000188:drug therapy*; D006801:Humans; D016773:Leishmaniasis, Cutaneous / Q000188:drug therapy*; D008297:Male; D010303:Paromomycin / Q000008:administration & dosage* / Q000009:adverse effects
D000981:Antiprotozoal Agents; D001558:Benzethonium; D010303:Paromomycin; C005106:methylbenzethonium chloride
Erfolgreiche topische Behandlung der chronisch kutanen Leishmaniose mit Paromomycinsulfat (15%) und Methylbenzethoniumchlorid (12%).